Wyeth Medica Ireland

 Profile   News 

Wyeth is investing more than $1 billion to expand its production facilities in Ireland with the construction of a multi-product biopharmaceutical Campus at Grange Castle. Located at a new 90-acre site on the Grange Castle International Business Park in Clondalkin, Dublin, the new Campus will employ 1,300 people at full production - bringing the total Wyeth workforce in Ireland to 3,000.

The Wyeth BioPharma Campus at Grange Castle , BioPharma Jobs, P.O. Box 1157, Dublin 12
Telephone:(Within Ireland)1850 930 930 Outside Ireland +353

Main Contacts
Mr Enda Doyle

Wyeth already operates 3 facilities in Ireland, producing pharmaceuticals, infant formula products, and animal vaccines. The Wyeth BioPharma Campus at Grange Castle is an expansion of Wyeth Medica Ireland operations.

The new Campus will manufacture a range of health care products for the treatment of patients suffering from serious illnesses, including rheumatoid arthritis and pneumonia in young children. Additionally, a treatment for spinal/facial surgery is in development. These products are currently manufactured at other Wyeth facilities around the world, and the new Campus at Grange Castle will help the company meet the growing demand for these successful products.

The Grange Castle site was selected for this project in the face of stiff competition from other locations, including sites in Puerto Rico and Singapore. However, Ireland was already familiar to Wyeth, which has operated in the country for the past 27 years and currently employs 1,700 people at its plants in Newbridge, Askeaton, and Sligo.

The project was announced by An Tanaiste, Mary Harney, T.D. on 4 April 2000, and is regarded by IDA Ireland as one of the most important projects won for Ireland.

Wyeth is absolutely delighted with the positive response that it has received from the business sector, community groups, and elected representatives in the Clondalkin area, and looks forward to making a significant contribution to the economic and social development of Clondalkin and South County Dublin in the future.

Grange Castle Facilities
The Wyeth BioPharma Campus at Grange Castle will comprise 3 separate facilities - a drug development facility, a drug substance facility, and a drug product facility. These facilities will go into production on a phased basis over the next 4 years.

The Drug Development Facility will move products from the research pipeline to commercial manufacturing. It will coordinate and validate the technologies and procedures required to migrate the products and processes from the laboratory to the commercial production stage.

The Drug Substance Facility will perform the beginning and intermediate stages of manufacture of cell culture products for worldwide distribution. It will be a multi-product facility that will include media preparation, fermentation, and purification stages of manufacture.

In the Finished Product Facility the finished products are placed in vials for end sale as sterile products. The primary steps of the finishing process are formulation, vial preparation, filling, capping, and inspection.